Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRG-514 in Breast-Conserving Cancer Surgery
NCT06300411Phase 1Completed
- Sponsor
- SURGE Therapeutics
- Start
- Jul 2024
- Primary completion
- Apr 2026
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SRG-514 in breast cancer, sponsored by SURGE Therapeutics. Primary endpoints: Incidence of dose-limiting toxicities at 14 days and Incidence of Treatment-Emergent Adverse Events up to 60 days. Started Jul 2024; status: completed.
02
Drugs
SRG-514
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06300411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06300411.